GlassScriptPhysician profile
Jonathan Lopez Oliver
NPI 1922327089
$1,144.90
in general payments reported to CMS, 2019-2025
17 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $475 · 2021: $113 · 2022: $12.23 · 2023: $47.91 · 2024: $57.79 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $323.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $402.09 | 2019-2024 | Shingrix, Bexsero, Arexvy |
| Revance Therapeutics, INC. | $141.96 | 2025 | Daxi |
| Allergan, INC. | $141.72 | 2019-2020 | |
| Lilly USA, LLC | $81.67 | 2019-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $62.31 | 2021-2025 | |
| Pfizer INC. | $49.61 | 2019-2020 | |
| Novo Nordisk INC | $36.67 | 2020 | |
| Daiichi Sankyo INC. | $36.08 | 2020 | |
| Gilead Sciences, INC. | $30.41 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.25 | 2024 | Fruzaqla |
| Kerecis Limited | $22.93 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Janssen Pharmaceuticals, INC | $18.12 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.99 | 2021 | |
| Amgen INC. | $16.05 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $15.69 | 2025 | Cologuard Collection Kit |
| Ge Healthcare | $15.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lopez Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.